Form 4: Arrowhead Director Sells 16,250 Shares

Arrowhead Pharmaceuticals Director Michael S. Perry sold 16,250 shares of common stock for a weighted average price of $61.03, executed under a Rule 10b5-1 plan.

Summary

• Michael S. Perry, a Director at Arrowhead Pharmaceuticals, Inc. (ARWR), sold 16,250 shares of common stock.
• The transaction occurred on December 5, 2025.
• The shares were sold at a weighted average price of $61.03 per share, with individual transaction prices ranging from $60.90 to $61.54.
• Following this transaction, Mr. Perry beneficially owns 115,240 shares of common stock.
• The sale was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• The remaining beneficial ownership includes previously reported shares of common stock underlying Restricted Stock Units, a portion of which are still subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: The filing is a standard disclosure of an insider stock sale, which is a neutral event when executed under a Rule 10b5-1 plan, indicating pre-planned personal financial management rather than a reaction to new information.

Negatives

• A director sold 16,250 shares of company stock, which can sometimes be perceived negatively by the market, even if executed under a pre-arranged plan.

Industry Context

This is a routine insider transaction disclosure for a biotechnology company. Such sales are common for executives and directors for personal financial planning, especially when executed under a Rule 10b5-1 plan, which pre-schedules trades to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders may note the director's sale, though the Rule 10b5-1 plan mitigates concerns about trading on non-public information.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Michael S. Perry, Insider Sale, Form 4, Director, Stock Transaction, Rule 10b5-1